Skip to content

US · DRIO · MEDICAL - DIAGNOSTICS & RESEARCH

DarioHealth Corp. (DRIO) intrinsic value and stock valuation

$1.32as of 2026-11-21 · Mkt cap 56.01M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

DarioHealth Corp. DCF and intrinsic value

InvestorsCraft values DRIO with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from DRIO’s statements →

DarioHealth Corp. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research New York City, NY 10011 dariohealth.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$22.4M+24.2% 5y CAGRd
20122025
Net income
-$-41.71M
20122025
Free cash flow
-$-26.08M
20122025
Total equity
$67.9M+19.3% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$22.4M$27M$20.4M$27.7M$20.5M
Operating income-$-36.66M-$-57.74M-$-56.19M-$-56.81M-$-76.49M
Net income-$-41.71M-$-42.75M-$-59.43M-$-62.19M-$-76.76M
EPSd-$-840.42K-$-1.06M-$-2.09M-$-2.63M-$-4.63M
Operating cash flow-$-25.94M-$-38.56M-$-30.38M-$-47.84M-$-50.41M
Capital expenditure-$-140K-$-140K-$-580K-$-570K-$-260K
Free cash flow-$-26.08M-$-38.7M-$-30.96M-$-48.42M-$-50.67M
Total assets$110.1M$118.9M$96.4M$119.2M$100.8M
Total debt$31.8M$30.2M$29.5M$28.1M$290K
Net debt$5.5M$2.43M-$-7.26M-$-21.31M-$-35.71M
Total equity$67.9M$72M$58.1M$80M$85.6M
Cash and short-term investments$26.3M$28.5M$36.8M$49.4M$36M
Income statement
20252024202320222021
Revenue$22.4M$27M$20.4M$27.7M$20.5M
Cost of revenue$9.69M$13.8M$14.4M$18M$12.4M
Gross profit$12.7M$13.3M$5.98M$9.65M$8.07M
Research and development expenses$13.8M$24.2M$20.3M$19.7M$17.2M
Selling, general and administrative expenses$35.5M$46.8M$41.8M$46.8M$62.4M
Other expenses$0.00$0.00$130K$0.00$4.99M
Operating expenses$49.3M$71M$62.2M$66.5M$84.6M
Cost and expenses$59M$84.8M$76.4M$84.5M$97M
Interest income$940K$1.12M$1.87M$510K$40K
Interest expense$3.36M$100K$650K$2.68M$80K
Depreciation and amortization$3.56M$7.43M$4.99M$4.72M$4.46M
Ebitda-$-34.69M-$-37.08M-$-54.38M-$-55.6M-$-70.02M
Operating income-$-36.66M-$-57.74M-$-56.19M-$-56.81M-$-76.49M
Total other income/expenses, net-$-4.95M$13.1M-$-3.17M-$-5.38M-$-230K
Income before tax-$-41.61M-$-44.6M-$-59.36M-$-62.19M-$-76.73M
Income tax expense$100K-$-1.85M$60K$0.00$30K
Net income-$-41.71M-$-42.75M-$-59.43M-$-62.19M-$-76.76M
Weighted average shares outstanding$49.6M$40.4M$28.4M$23.6M$16.6M
Weighted average diluted shares outstanding$49.6M$40.4M$28.4M$23.6M$16.6M
Balance sheet
20252024202320222021
Cash and short-term investments$26.3M$28.5M$36.8M$49.4M$36M
Net receivables$2.67M$5.35M$3.64M$6.42M$1.79M
Inventory$4.32M$4.75M$5.06M$7.96M$6.23M
Total current assets$34.8M$40.5M$47.3M$65.5M$45.6M
Property, plant and equipment, net$1.27M$1.77M$1.87M$1.99M$990K
Goodwill and intangible assets$73.4M$76.2M$47M$51.6M$54.1M
Long-term investments$80K$0.00$10K$10K$20K
Total non-current assets$75.3M$78.4M$49.1M$53.7M$55.2M
Total assets$110.1M$118.9M$96.4M$119.2M$100.8M
Accounts payable$2.93M$3.04M$1.13M$2.32M$5.11M
Short-term debt$430K$5.96M$4.07M$9.12M$270K
Deferred revenue$710K$1.58M$1M$1.32M$1.2M
Total current liabilities$9.32M$16.6M$12.5M$19.4M$14.4M
Long-term debt$31.3M$24.2M$25.5M$18.9M$20K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$32.8M$30.2M$25.8M$19.8M$850K
Capital lease obligations$570K$1.27M$1M$1.12M$20K
Total liabilities$42.2M$46.9M$38.2M$39.2M$15.2M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-452.08M-$-390.34M-$-349.36M-$-285.85M-$-222.01M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$67.9M$72M$58.1M$80M$85.6M
Total investments$80K$700K$10K$10K$20K
Total debt$31.8M$30.2M$29.5M$28.1M$290K
Net debt$5.5M$2.43M-$-7.26M-$-21.31M-$-35.71M
Cash flow statement
20252024202320222021
Net income-$-41.71M-$-42.75M-$-59.43M-$-62.19M-$-76.76M
Depreciation and amortization$2.83M$7.43M$4.99M$4.72M$4.46M
Stock-based compensation$9.37M$15.8M$19.7M$17M$25M
Change in working capital$2.21M-$-2.47M$4.07M-$-10.9M-$-2.57M
Accounts receivable$2.64M$1.6M$2.83M-$-5.11M-$-370K
Inventory$440K$310K$2.89M-$-1.73M-$-2.23M
Accounts payable-$-120K-$-500K-$-1.19M-$-2.79M$1.08M
Net cash provided by operating activities-$-25.94M-$-38.56M-$-30.38M-$-47.84M-$-50.41M
Investments in property, plant and equipment-$-140K-$-140K-$-580K-$-440K-$-260K
Acquisitions, net$0.00-$-8.8M$0.00$0.00-$-7.47M
Net cash used for investing activities-$-4.34M-$-8.93M-$-550K-$-570K-$-8.13M
Common stock issued$24.1M$0.00$1.61M$38.3M$64.9M
Common stock repurchased$0.00$0.00$0.00-$-130K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$24.3M$38.5M$18.3M$61.9M$65.8M
Net change in cash-$-5.96M-$-9.03M-$-12.67M$13.5M$7.22M
Cash at end of period$21.8M$27.8M$36.8M$49.5M$36M
Operating cash flow-$-25.94M-$-38.56M-$-30.38M-$-47.84M-$-50.41M
Capital expenditure-$-140K-$-140K-$-580K-$-570K-$-260K
Free cash flow-$-26.08M-$-38.7M-$-30.96M-$-48.42M-$-50.67M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About DarioHealth Corp.

        DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management. They also offer 'Dario Musculoskeletal' for preventing and treating common MSK conditions, and 'Dario' behavioral health solutions to improve access to evidence-based care. Their offerings extend to general chronic condition management solutions and DarioEngage, a proprietary care management platform. In terms of hardware, DarioHealth provides smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, biofeedback sensor devices, and disposables such as test strip cartridges and lancets for blood glucose monitoring systems. Furthermore, they offer comprehensive diabetes management programs that integrate lifestyle changes, healthy eating guidance, advanced tracking tools, and live coaching. Founded in 2011, the company was formerly known as LabStyle Innovations Corp. before officially changing its name to DarioHealth Corp. in July 2016. Its headquarters are located in New York, New York.

        CEO
        Erez Raphael
        Employees
        163
        Beta
        1.09

        Explore

        Frequently asked questions

        What is the intrinsic value of DarioHealth Corp. (DRIO)?

        InvestorsCraft does not currently publish an intrinsic value for DRIO. How the IC value is calculated.

        Is DRIO undervalued?

        InvestorsCraft does not publish an undervaluation signal for DRIO at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.